Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 599 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumors Metastatic to Brain Clear all
Completed Not applicable Interventional Results available

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

NCT04796935
View directory record Official record
Conditions
Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer, Obstetric Procedure Pain, Orthopedic Procedure Pain, Post-Dural Puncture Headache
Interventions
Tactile Imaging (VerTouch), Control (palpation)
Device · Other
Lead sponsor
IntuiTap Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Providence, Rhode Island • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab In Central Nervous System Metastases

NCT02886585
View directory record Official record
Conditions
Brain Metastases
Interventions
Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT05640193
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel (LN-144)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

NCT02279992
View directory record Official record
Conditions
Glioma, Brain Neoplasms, Brain Metastasis
Interventions
Vardenafil, Carboplatin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

Pembro+Chemo in Brain Mets

NCT04964960
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
Interventions
Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Phase I Study of Fractionated Stereotactic Radiation Therapy

NCT03726359
View directory record Official record
Conditions
Brain Metastases
Interventions
Fractionated Stereotactic Radiation Therapy (FSRT)
Radiation
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

NCT00389584
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Poor Performance Status, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, cognitive assessment, management of therapy complications, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT05843253
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Ribociclib, Everolimus, Temozolomide (TMZ)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

NCT05588453
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Natural Killer Cell Therapy, Temozolomide
Biological · Drug
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging

NCT02311556
View directory record Official record
Conditions
Brain Metastases
Interventions
dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions

NCT04047264
View directory record Official record
Conditions
Glioma, Glioblastoma, Metastatic Malignant Neoplasm in the Brain
Interventions
Microdialysis, Magnetic Resonance Imaging, Computed Tomography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional Results available

Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma

NCT00105560
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
radiation therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

NCT07227610
View directory record Official record
Conditions
Brain Metastases, Cancer (With CNS Involvement)
Interventions
Staged Stereotactic Radiosurgery (SSRS), Fractionated Stereotactic Radiotherapy (FSRT)
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

NCT01266967
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
GSK2118436
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting No phase listed Observational

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

NCT05480644
View directory record Official record
Conditions
Brain Tumor, Primary, Brain Metastases, Adult
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

NCT02132598
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

NCT03175432
View directory record Official record
Conditions
BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Melanoma
Interventions
Atezolizumab, Bevacizumab, Cobimetinib, Quality-of-Life Assessment
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Withdrawn Phase 2 Interventional

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

NCT01736800
View directory record Official record
Conditions
Central Nervous System (CNS) Metastases, Brain Metastases
Interventions
Topotecan, Temozolomide
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Not applicable Interventional Results available

Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection

NCT04040400
View directory record Official record
Conditions
Brain Metastases
Interventions
intraoperative radiotherapy (IORT)
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

DM-CHOC-PEN for Brain Tumors in AYA Subjects

NCT03668847
View directory record Official record
Conditions
Advanced Cancer, Brain Metastases
Interventions
DM-CHOC-PEN
Drug
Lead sponsor
DEKK-TEC, Inc.
Industry
Eligibility
15 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

NCT02260531
View directory record Official record
Conditions
Breast Cancer, Brain Tumor - Metastatic
Interventions
Cabozantinib, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 26, 2026, 10:47 PM EDT